2012•Proceeding of Clinical MedicineRequires access

Effects of epimedium on inflammatory factor of type 2 diabetic mellitus rats

Shan Gao

Open publisher page 0 citations

Abstract

Objective:To investigate the effect of epimedium on inflammatory factor in type 2 diabetic rats.Methods:Ten normal rats(normal control group)was selected from 70 diabetic rats,others was feeded by high-glucose and high-fat diet and injected streptozocin,these models with type 2 diabetic were randomly divided into diabetes mellitus(DM) model group(16 rats),epimedium group(16 rats) and metformin group(12 rats).These group were given medical for 8 weeks.We observed their blood glucose(FBG),C reaction protein(CRP),tumor necrosis factor-α(TNF-α),interleukin-6(IL-6).Results:Blood glucose,CRP,TNF-α,IL-6 were significantly higher in type 2 diabetic rats groups than in normal control group(P0.01).Compared with DM model group,blood glucose,CRP,TNF-α,IL-6 were significantly decreased in epimedium group and metformin group(P0.05).There was no significant difference between epimedium group and metformin group.Conclusion:Epimedium could reduce the level of inflammatory factor and inhibit inflammatory reaction.

About this research paper

What this paper is about

Objective:To investigate the effect of epimedium on inflammatory factor in type 2 diabetic rats.Methods:Ten normal rats(normal control group)was selected from 70 diabetic rats,others was feeded by high-glucose and high-fat diet and injected streptozocin,these models with type 2 diabetic were randomly divided into diabetes mellitus(DM) model group(16 rats),epimedium group(16 rats) and metformin group(12 rats).These group were given medical for 8 weeks.We observed their blood glucose(FBG),C reaction protein(CRP),tumor necrosis factor-α(TNF-α),interleukin-6(IL-6).Results:Blood glucose,CRP,TNF-α,IL-6 were significantly higher in type 2 diabetic rats groups than in normal control group(P0.01).Compared with DM model group,blood glucose,CRP,TNF-α,IL-6 were significantly decreased in epimedium group and metformin group(P0.05).There was no significant difference between epimedium group and metformin group.Conclusion:Epimedium could reduce the level of inflammatory factor and inhibit inflammatory reaction.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective:To investigate the effect of epimedium on inflammatory factor in type 2 diabetic rats.Methods:Ten normal rats(normal control group)was selected from 70 diabetic rats,others was feeded by high-glucose and high-fat diet and injected streptozocin,these models with type 2 diabetic were randomly divided into diabetes mellitus(DM) model group(16 rats),epimedium group(16 rats) and metformin group(12 rats).These group were given medical for 8 weeks.We observed their blood glucose(FBG),C reaction protein(CRP),tumor necrosis factor-α(TNF-α),interleukin-6(IL-6).Results:Blood glucose,CRP,TNF-α,IL-6 were significantly higher in type 2 diabetic rats groups than in normal control group(P0.01).Compared with DM model group,blood glucose,CRP,TNF-α,IL-6 were significantly decreased in epimedium group and metformin group(P0.05).There was no significant difference between epimedium group and metformin group.Conclusion:Epimedium could reduce the level of inflammatory factor and inhibit inflammatory reaction.

Key concepts: Epimedium, Metformin, Streptozocin, Medicine, Internal medicine, Type 2 Diabetes Mellitus, Endocrinology, Tumor necrosis factor alpha

Related papers

Back to paper searchBrowse research topicsOriginal source
Effects of epimedium on inflammatory factor of type 2 diabetic mellitus rats — Research Paper | ScholarLens